Clinical features, therapeutic requirements and evolution of patients with Crohn's disease and upper gastrointestinal involvement (CROHNEX study).
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
revised:
17
05
2021
received:
07
05
2021
accepted:
13
07
2021
pubmed:
19
8
2021
medline:
14
10
2021
entrez:
18
8
2021
Statut:
ppublish
Résumé
Crohn's disease (CD) with upper gastrointestinal involvement (UGI) may have a more aggressive and refractory course. However, evidence on this phenotype of patients is scarce. To identify the clinical characteristics, therapeutic requirements and complications associated with UGI in CD METHODS: Nationwide study of cases (UGI, UGI plus ileal/ileocolonic involvement) paired with controls (ileal/ileocolonic involvement) from the ENEIDA registry. Cases were matched to 2 controls by year of diagnosis ± 2.5 years. Patients with exclusive/predominant colonic location or complex perianal fistula were excluded. Of 24 738 patients with CD in the ENEIDA registry, we identified 4058 with UGI (16% of the total CD cohort). Finally, 854 cases and 1708 controls were included. Cases were independently associated to extensive involvement (OR 2.7 [2.2-3.3], P < 0.0001), strictures [OR 1.8 (1.5-2.2), P < 0.0001], chronic iron deficiency anaemia [OR 2.2 (1.3-3.2), P < 0.001] and use of second-line biologics [OR 1.7 (1.1-2.6), P = 0.021]. The median stricture-free time was 14 years (95% CI, 12-16) for cases vs 21 years (95% CI, 19-23) for controls (P < 0.0001). Cases with isolated UGI compared to UGI plus ileal/ileocolonic more frequently had localised disease [OR 0.5(0.3-0.8), P = 0.003] and underwent more endoscopic stricture dilations [OR 2.7(1.3-5.4), P = 0.006]. The largest cohort of patients with CD and UGI provides information on the natural history of this particular phenotype. Increased awareness of the clinical picture and therapeutic requirements of these patients could lead to earlier diagnosis and treatment of upper gastrointestinal lesions, preventing the structural damage frequently seen in these patients at diagnosis and during follow-up.
Sections du résumé
BACKGROUND
Crohn's disease (CD) with upper gastrointestinal involvement (UGI) may have a more aggressive and refractory course. However, evidence on this phenotype of patients is scarce.
AIMS
To identify the clinical characteristics, therapeutic requirements and complications associated with UGI in CD METHODS: Nationwide study of cases (UGI, UGI plus ileal/ileocolonic involvement) paired with controls (ileal/ileocolonic involvement) from the ENEIDA registry. Cases were matched to 2 controls by year of diagnosis ± 2.5 years. Patients with exclusive/predominant colonic location or complex perianal fistula were excluded.
RESULTS
Of 24 738 patients with CD in the ENEIDA registry, we identified 4058 with UGI (16% of the total CD cohort). Finally, 854 cases and 1708 controls were included. Cases were independently associated to extensive involvement (OR 2.7 [2.2-3.3], P < 0.0001), strictures [OR 1.8 (1.5-2.2), P < 0.0001], chronic iron deficiency anaemia [OR 2.2 (1.3-3.2), P < 0.001] and use of second-line biologics [OR 1.7 (1.1-2.6), P = 0.021]. The median stricture-free time was 14 years (95% CI, 12-16) for cases vs 21 years (95% CI, 19-23) for controls (P < 0.0001). Cases with isolated UGI compared to UGI plus ileal/ileocolonic more frequently had localised disease [OR 0.5(0.3-0.8), P = 0.003] and underwent more endoscopic stricture dilations [OR 2.7(1.3-5.4), P = 0.006].
CONCLUSIONS
The largest cohort of patients with CD and UGI provides information on the natural history of this particular phenotype. Increased awareness of the clinical picture and therapeutic requirements of these patients could lead to earlier diagnosis and treatment of upper gastrointestinal lesions, preventing the structural damage frequently seen in these patients at diagnosis and during follow-up.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1041-1051Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Freeman HJ. Natural history and long-term clinical course of Crohn’s disease. World J Gastroenterol. 2014;20:31-36.
Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5A-36A.
Mao R, Tang R-H, Qiu Y, et al. Different clinical outcomes in Crohn’s disease patients with esophagogastroduodenal, jejunal, and proximal ileal disease involvement: is L4 truly a single phenotype? Therap Adv Gastroenterol. 2018;11:1-9.
Chow DKL, Sung JJY, Wu JCY, Tsoi KKF, Leong RWL, Chan FKL. Upper gastrointestinal tract phenotype of Crohn’s disease is associated with early surgery and further hospitalization. Inflamm Bowel Dis. 2009;15:551-557.
Park S-K, Yang S-K, Park SH, et al. Long-term prognosis of the jejunal involvement of Crohn’s disease. J Clin Gastroenterol. 2013;47:400-408.
Lazarev M, Huang C, Bitton A, et al. Relationship between proximal Crohn’s disease location and disease behaviour and surgery: a cross-sectional study of the IBD genetics consortium. Am J Gastroenterol. 2013;108:106-112.
Kim OZ, Han DS, Park CH, et al. The clinical characteristics and prognosis of Crohn’s disease in Korean patients showing proximal small bowel involvement: results from the CONNECT study. Gut Liv. 2018;12:67-72.
Ruffa A, Angelucci E, Petruzziello C, et al. Jejunal Crohn's disease: characteristics, outcome, need of surgery and immunomodulators in a restrospective single-center study. Dig Liver Dis. 2016;48:197-198.
Koutroubakis IE, Ramos-Rivers C, Regueiro M, et al. Persistent or recurrent anemia is associated with severe and disabling Inflammatory bowel disease. Clin Gastroenterol Hepatol. 2015;13:1760-1766.
Burisch J, Vegh Z, Katsanos K, et al. for the EpiCom study group. Occurence of anemia in the first year of inflammatory bowel disease in a European population-based inception cohort - an ECCO-EpiCom study. J Crohn’s Colitis. 2017;11(10):1213-1222.
Zabana Y, Panés J, Nos P, et al. on behalf of GETECCU. The ENEIDA registry (Nationwide study on genetic and environmental determinants of inflammatory bowel disease) by GETECCU: design, monitoring and functions. Gastroenterol Hepatol. https://doi.org/10.1016/j.gastrohep.2020.05.007. Published May 19, 2020
Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377-381.
Louis E, Collard A, Oger AF, Degroote E, El Yafi FAN, Belaiche J. Behavior of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001;49:777-782.
Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17:1314-1321.
Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785-1794.
Cleynen I, Boucher G, Jostins L, et al. Inherited determinants of Crohn’s disease and ulcerative colitis phenotypes: a genetic association study. Lancet 2016;387:156-167.
Zabana Y, Garcia-Planella E, van Domselaar M, et al. Predictors of favourable outcome in inflammatory Crohn's disease. A retrospective observational study. Gastroenterol Hepatol. 2013;36:616-623.
Domènech E, Hinojosa J, Nos P, et al. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated? Aliment Pharmacol Ther. 2005;22:1107-1113.
Bemelman WA, Warusavitarne J, Sampietro GM, et al. on behalf of the European Crohn’s and Colitis Organisation [ECCO] and the European Society of Colo-Proctology [ESCP]. ECCO-ESCP consensus on surgery for Crohn’s disease. J Crohns Colitis. 2018;12:1-16.
Gomollon F, Dignass A, Annese V, et al., on behalf of ECCO. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11(1):3-25.
Dignass AU, Gasche C, Bettenworth D, et al. on behalf of ECCO. ECCO Guideline/Consensus Paper European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases. J Crohns Colitis. 2015;9:211-222.
Greuter T, Piller A, Fournier N, et al. on behalf of the Swiss IBD Cohort Study Group. Upper gastrointestinal tract involvement in Crohn’s disease: frequency, risk factors, and disease course. J Crohns Colitis. 2018;12:1399-1409.
Horjus Talabur Horje CS, Meijer J, Rovers L, van Lochem EG, Groenen MJM, Wahab PJ. Revalence of upper gastrointestinal lesions at primary diagnosis in adults with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:1896-1901.
Annunziata ML, Caviglia R, Papparella LG, Cicala M. Upper gastrointestinal involvement of Crohn’s Disease: a prospective study on the role of upper endoscopy in the diagnostic work-up. Dig Dis Sci. 2012;57:1618-1623.
González-Suárez B, Rodriguez S, Ricart E, et al. Comparison of capsule endoscopy and magnetic resonance enterography for the assessment of small bowel lesions in Crohn's Disease. Inflamm Bowel Dis. 2018;24:775-780.